Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the Jefferies' 2017 Celgene Collaborators Summit in New York City, USA, and will be attending the Bankhaus Lampe German Equity Forum, London, UK, and the 11th ODDO German Conference, Frankfurt, Germany.
Bankhaus Lampe German Equity Forum, London, UK
Date: Thursday, 02 February 2017
Venue: London, UK
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
11th ODDO German Conference, Frankfurt, Germany
Date: Thursday, 16 February 2017
Venue: Frankfurt, Germany
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
Jefferies' 2017 Celgene Collaborators Summit, New York City, USA
Date: Tuesday, 21 February 2017
Venue: New York City, USA
Attendee: Dr Werner Lanthaler, Chief Executive Officer of Evotec AG
ABOUT EVOTEC
AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 70 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. Janssen Pharmaceuticals in the field of Alzheimer's disease, with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and with Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
| Language: | English | |
| Company: | Evotec AG | |
| Manfred Eigen Campus / Essener Bogen 7 | ||
| 22419 Hamburg | ||
| Germany | ||
| Phone: | +49 (0)40 560 81-0 | |
| Fax: | +49 (0)40 560 81-222 | |
| E-mail: | ||
| Internet: | ||
| ISIN: | DE0005664809 | |
| WKN: | 566480 | |
| Indices: | TecDAX | |
| Listed: | Regulated Market in Frankfurt (Prime Standard); | |
Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, | ||
| Munich, Stuttgart, Tradegate Exchange |
View source version on businesswire.com: http://www.businesswire.com/news/home/20170130005644/en/
Contacts:
Gabriele Hansen, VP Corporate Communications & Investor
Relations
Phone: +49.(0)40.56081-255
gabriele.hansen@evotec.com
